7 Best Behavioral Health M&A Advisors: SUD, Mental Health & ABA in 2026

7 Best Behavioral Health M&A Advisors: SUD, Mental Health & ABA in 2026

Last updated: September 2026 · Last verified: September 2026

TL;DR. "Behavioral health M&A" is three markets moving in opposite directions, the Two-Speed Behavioral Market: autism services deal flow is running up 58% on 2025, substance use disorder down 28%, the aggregate up 3.4% (The Braff Group, Mid-Year 2026 Update), while Q2 2026 produced 27 closed transactions, 21 of them traditional M&A, the lightest quarter for closed traditional volume in its data set going back to 2022, and two addiction treatment deals, the lowest quarterly total in its data set (Mertz Taggart, Q2 2026 report). Nobody agrees what 2025 did: +2.3%, +17% and +44.1% are three published counts of one year, the Three-Counter Problem. The only filed multiples are Wells Fargo Securities' in Talkspace's proxy, a 15.0x median NTM adjusted EBITDA on precedents and 10.1x on public comparables, behind the $5.25-per-share sale to Universal Health Services that closed August 17, 2026 (Talkspace DEFM14A, April 20, 2026; closing per its 8-K and Form 25-NSE of August 17, 2026). The Medicaid law sellers fear expressly excludes mental health and SUD services from cost sharing, and its work requirement starts no later than January 1, 2027 with SUD, disabling-mental-disorder and IDD exemptions (Public Law 119-21). Ranked on adviser-of-record evidence: Brentwood Capital Advisors, The Braff Group, VERTESS, Wells Fargo Securities, J.P. Morgan, Provident Healthcare Partners and Mertz Taggart. I run Peony, the data room 6,800+ teams use for processes like these; we are not an adviser.

Why is "behavioral health" three M&A markets moving in opposite directions in 2026?

Because substance use disorder, mental health and autism/ABA are paid by three different payer mixes, bought by three different buyer sets and, in 2026, moving three different ways. I'm Sean Yu, co-founder of Peony, a data room company. I have built and watched thousands of data rooms across my career — about 1,000 of those when I was an investor at two funds with a combined $6.3 billion in AUM, and the rest across the 6,800+ teams Peony serves today, where the founders we work with have raised over $18 billion to date. This guide is for a residential or outpatient SUD operator, an outpatient mental health or psychiatry group and an ABA or IDD provider, each priced by a different buyer on a different payer mix. Eating-disorder treatment is the fourth lane, and the honest finding is that no counter tracks it separately.

A behavioral health M&A advisor is an investment bank or sell-side boutique that runs the sale, recapitalization or capital raise of a behavioral provider on the owner's behalf: positioning payer mix and census, building the buyer list of sponsor platforms, strategics and, newly in 2026, nonprofits, and managing the licensure and change-of-ownership calendar that usually sets the closing date. This post sits under the best M&A advisors hub, deepens the behavioral section of our best healthcare M&A advisors guide, and mirrors the best dental M&A advisors spoke.

I built the bench on one standard, the Adviser-of-Record Ledger, a Peony-original evidence standard: a firm earns a rank only if I could find a behavioral adviser-of-record credit in a primary source, an SEC filing, a counterparty's release, a dated trade-press report naming the role, or the firm's own tombstone with the role stated; where the evidence is undated or unregistered, the profile says so.

The 2026 tape is two reports that sound contradictory and are not. The Braff Group's Mid-Year 2026 Update has the sector "poised to eclipse last year's tally by 3.4%," on big swings, positive and negative, in two sub-segments:

Mertz Taggart's Q2 2026 Behavioral Health M&A Report, published August 2026, counts closings in one quarter rather than annualising a half-year: 27 closed transactions, 21 traditional M&A deals and 6 growth deals, with traditional M&A volume down from 34 closed deals in Q1 2026 and 29 in Q2 2025, which the firm calls the lightest quarter for closed traditional volume in its data set going back to 2022. By sub-sector, mental health fell to 14 closings from 18 in Q1 2026 and 20 in Q2 2025, autism/IDD to 6 from 10 and 7, and addiction treatment to 2 from 6 and 7, "the lowest quarterly total in our data set." Kevin Taggart's read: "SUD is where the gap between good assets and everything else is widest right now. Platforms are still looking, but they're selective on payer mix and length of stay, and some are still cleaning up what they bought in 2021 and 2022. For a quality operator, there's very little competing supply." Braff annualises first-half data across a broader definition; Mertz reports closings in one quarter. Both are true, and the honest headline is neither "booming" nor "collapsing": the aggregate is flat-to-slightly-up while the sub-markets diverge, for one reason, the payer mix each lane runs on. That is the Two-Speed Behavioral Market.

Which behavioral health M&A counter should I believe for 2025 and 2026?

None of them alone, because three respected, free, primary-sourced counters publish three different numbers for the same year. Call it the Three-Counter Problem, a Peony-original diagnosis.

They count different universes, closed versus announced, with or without growth rounds and adjacent services; never blend them and never average them. Mertz's 2025 sub-sector split is the most granular public figure available: 111 mental health, 36 autism/IDD and 33 addiction treatment deals, as tracked by Mertz Taggart, with its own footnote that "total industry transactions do not necessarily equal the sum of the sub-industries, as many transactions include more than one sub-industry." And every count understates sponsor add-ons: Taggart reports "several deals in 2025 that the private equity backed acquirer didn't want the deal announced."

Which advisers actually closed the behavioral health deals on the tape, 2020-26?

One large-cap pair on the only public-company deal, and one Nashville bank on the only dated private ones. The Adviser-of-Record Ledger below is every behavioral transaction where I could read the adviser's role in a primary document.

Bottom line: twelve deals, and the dated adviser-of-record evidence in private behavioral health comes almost entirely from one firm. I opened Brentwood's Georgia Recovery Campus page and read "served as the exclusive financial advisor to Georgia Recovery Campus"; the other nine credits are as its transactions index states them, each tile carrying "Transaction year" and a stated service, "Sell-Side Advisory" on eight of them and "Buy-Side Advisory" on the Comvest credit, where Brentwood advised the buyer.

Most behavioral deals name no adviser at all. The 2025-26 tape in Mertz Taggart's Q4 2025 and Q2 2026 reports is a buyer map, not an adviser map: Merakey's acquisition of I Am Boundless, the largest behavioral deal of Q2 2026 in any sub-sector, a Pennsylvania nonprofit combining with a provider that grew from $20 million to an expected $200 million of revenue in seven years, "up to $1 billion in annual revenue" combined; Gryphon-backed LEARN Behavioral's purchase of Little Leaves Behavioral Services from FullBloom (Behavioral Health Business, May 12, 2026); and Brightli's merger with Centerstone (Q4 2025). Two were pending at the end of Q2 2026 per Mertz Taggart and are carried as pending here, the status as of that report and not re-verified since, checked September 15, 2026: Clearview Capital's agreed exit of Advantage Behavioral Health to the nonprofit QCF/I, Inc., financed by a planned $610 million municipal bond issuance; and HPS Investment Partners' agreed majority ownership of Discovery Behavioral Health in exchange for a substantial debt reduction, subject to regulatory approval. A list that says a firm "advised on" any of these without a filing, a dated tombstone or a party's release is asserting, not reporting.

Who are the 7 behavioral health M&A advisors on this bench, and how are they ranked?

By behavioral adviser-of-record evidence first and by relevance to an owner-seller second. A counterparty's SEC filing outranks a firm's own dated tombstones, which outrank undated tombstones with the role and both parties stated, which outrank research without deals; repeat evidence at the size this guide's readers sell at outranks a single filed credit at platform scale, which is why Brentwood and Braff sit above Wells Fargo Securities, and why positions 4 and 5, one filed credit each, are the bank across the table below roughly $500 million rather than your hire. Provident sits below the two banks because three undated tombstones are not repeat evidence on the scale of Brentwood's ten dated or VERTESS's 112 role-labelled credits: a filed credit outranks a thin undated set, and a deep undated set outranks a filed credit.

1. Brentwood Capital Advisors: the only firm that publishes the date

Brentwood Capital Advisors, Nashville, states "250+ Total transactions closed," "$40B+ Total transaction value," "30+ Years of average partner experience" and "1999 Year Founded." Its transactions index merchandises four behavioral categories in its own words, "Addiction and Mental Health Treatment," "Autism Services," "Substance Use Disorder Treatment" and "Mental Health Treatment," and the ten credits in the ledger span all three lanes; nine are sell-side and the Comvest credit is buy-side, Brentwood as financial advisor to the acquirer. Registration: Brentwood Capital Advisors LLC, CRD 118712 in the SEC adviser-info database; no FINRA/SIPC statement appears on the homepage, so the record is with the regulator, not on the site. Verdict: first on adviser-of-record evidence because it is the only bench firm a seller can check, deal by deal, year by year; the specialists below have more behavioral deals, but on their own pages you have to take their word for when.

2. The Braff Group: the deepest buyer map, with the banker's name on every deal

The Braff Group, 1665 Washington Road, Suite 3, Pittsburgh, describes itself as "Leading Sell-Side Health Care M&A Advisors" with "28 years of experience" and "nearly 400 successful transactions in health care services"; behavioral health is listed first among its seven sectors and Dexter W. Braff is its president. Its transaction sitemap held 380 pages on September 15, 2026, our count, and every page states "BRAFF WAS SELLSIDE ADVISOR" and names the managing director who led it: Ted Jordan on a multi-location opioid treatment program and a school-based ABA provider, Steve Garbon on New Choices, Inc. to Caregiver, Inc. in IDD, Nancy Weisling on Walden to Pyramid Healthcare. The buyer map is the citable asset: BayMark Health Services three times, The Stepping Stones Group three times, LEARN Behavioral or LEARN It four times, Webster Equity Partners twice in IDD, Refresh Mental Health twice, plus Lifeskills South Florida to Odyssey Behavioral Healthcare and Atlanta Center for Eating Disorders to Walden Behavioral Care. Not one of the 380 pages carries a date; the sitemap timestamps are CMS edits, not closings, and where a Braff date exists it is in a counterparty's release, as with our healthcare hub's Beneficial In-Home Care (February 13, 2025), not on Braff's page, and I found none for the behavioral credits. Registration: none stated on the site and zero SEC adviser-info records. Verdict: first on relationship evidence and on who-do-I-call precision; second overall only because of the date gap, which the firm can close in one meeting with three dated closes.

3. VERTESS: the broadest coverage, and the IDD and nonprofit corner

VERTESS is "headquartered in Dallas-Fort Worth," with nine other offices including Tucson, and names two behavioral sectors among its fifteen: "SUD/Behavioral Health" and "Intellectual/Developmental Disabilities and Autism Services." Its previous-transactions page lists 112 role-labelled deals with both parties named, 103 sell-side, 8 buy-side and 1 merger advisory, our count, and it is the only firm here with published credits in mental health, SUD, IDD and autism-adjacent services, and the only one with a merger-advisory credit and nonprofit-to-nonprofit sales. IDD credits include Share and Kare and Mosaic's Texas operations to Caregiver, Inc. and Community Resource Network of Florida to VersiCare Group. Its one dated behavioral credit in a primary release I could open is Momentum, a Maine behavioral provider, to Mosaic, November 15, 2024; our healthcare hub records two further dated VERTESS behavioral closes from the firm's own announcements, Shorehaven, a Maryland IDD provider, to Sevita in late April 2025 and a Connecticut Mental Health Specialists transaction between December 2025 and January 2026, neither re-verified this pass, so neither is in the ledger. VERTESS was "#1 lower middle market sell-side M&A advisor on Axial's 2024 Healthcare Top 50 list," a 2024 award. Registration: no FINRA/SIPC or "securities offered through" statement anywhere on the site, and zero adviser-info records. Verdict: the call for an IDD, waiver-funded or nonprofit seller, and for a Southwest operator; ask for dates, because the page gives you one.

4. Wells Fargo Securities: the sell side of the only filed behavioral deal, and the sector's conflicts lesson

Wells Fargo Securities, LLC advised Talkspace on its $5.25-per-share cash sale to Universal Health Services, delivering its fairness opinion on March 6, 2026, and the proxy is the sector's only filed price walk: from UHS's December 17 offer of "between $4.05 and $4.25 per share" to a signed $5.25, an increase the proxy describes as approximately 30%. The proxy is also the best "ask your adviser this" document in behavioral health: Wells Fargo disclosed that in the two years before its opinion it and its affiliates had investment or commercial banking relationships with UHS, the buyer, for "a fee of approximately $630,000"; that it held, on a proprietary basis, approximately 5% of Talkspace's outstanding shares; and that Douglas L. Braunstein, whose HEC Master Fund LP signed a voting agreement with UHS on March 9, 2026, "is currently a Vice Chairman of Wells Fargo & Company." All three were disclosed and none is improper; ask any adviser for the same disclosure in writing. Verdict: the template for a public-company sale and the source of the only filed comp set; no evidence below platform scale.

5. J.P. Morgan: the buy side of Talkspace

J.P. Morgan advised Universal Health Services on Talkspace; the proxy's "Background of the Merger" repeatedly records Wells Fargo conveying the Board's counterproposals "to representatives of J.P. Morgan." The filed deal-protection terms: Talkspace's termination fee landed at 3.75% of fully diluted equity value after it had sought 2.00% with a reverse termination fee, and UHS gave none for a regulatory failure. Verdict: ranked because the credit is SEC-filed; one credit, at scale, and the bank most likely to sit across from you if a public strategic bids.

6. Provident Healthcare Partners: ABA credits and the cleanest registration chain

Provident Healthcare Partners, One Financial Center, Boston, with offices in Minneapolis and New York, has provided healthcare investment banking "for over two decades." Its three behavioral transaction pages, all undated, each state the role: Beacon Behavioral Hospital to Latticework Capital Management ("served as the exclusive financial advisor," seven intensive outpatient locations and four inpatient hospitals; the client places it "in the middle of COVID," no year stated); Comprehensive Autism Center, a Southern California ABA provider, to The Speech Pathology Group; and New England ABA, Inc. to The Stepping Stones Group. Managing Director Rebecca Leiba is the named behavioral banker. Registration, verbatim from the footer: "Securities offered through PCF Capital Markets, LLC, Member FINRA/SIPC," confirmed as CRD 290765; the brand itself returns zero records. No SUD or IDD transaction page exists on the site, so the hub's "long autism and behavioral track record" holds for ABA and one psychiatric-hospital sale, not for SUD or IDD. Verdict: the ABA and outpatient mental-health call, and the only firm here that publishes its broker-dealer chain.

7. Mertz Taggart: the counter the whole sector quotes

Mertz Taggart, "specializing exclusively in healthcare services" for "over twenty years," is the research authority: its Behavioral Health M&A Report has run every quarter since Q4 2020, with separate mental health, addiction treatment and IDD/autism pages, the only firm here that merchandises the three sub-markets separately. Managing Partner Kevin Taggart, CM&AP, Senior Managing Director Sandra Zervoudakis, Managing Director Peter Thiessen and Director of M&A Analytics Anke Stugk are the named team. It publishes no transaction count, no dated tombstone I could retrieve and no registration statement. Verdict: seventh on adviser-of-record evidence, first on data; hire it when you want the firm that counts the market advising on timing, and ask for the closings the site does not show.

How do I check whether a behavioral health M&A adviser is FINRA-registered, and why are the best specialists invisible on BrokerCheck?

Search the broker-dealer named in the firm's footer, not the brand on the door, and expect the three best behavioral specialists to return nothing. I ran the bench through the SEC's adviserinfo.sec.gov firm search, which returns both investment-adviser and FINRA broker-dealer records, on September 15, 2026, and the result is the Evidence Inversion, a Peony-original observation: the firms with the behavioral tombstones have no regulator record, and the firms with the regulator record have no behavioral tombstones I could open. Brentwood Capital Advisors is the only firm on both sides.

Two name traps make the search worse than empty: "PCF" also returns PCF Provident Capital Markets, Inc., CRD 42442, a different firm, and "Mertz" returns several similarly named firms, Mertz Associates (CRD 148668), Mertz Mergers (CRD 24601), Mertz Capital (CRD 307305) and Townsend Mertz, none of which is Mertz Taggart; type the CRD. The pattern is the market's normal shape, not a scandal: most lower-middle-market behavioral sales are asset sales, and many intermediaries operate under the federal M&A-broker exemption at 15 U.S.C. § 78o(b)(13). It stops being academic the moment your deal includes equity rollover into a sponsor platform's holding company, a securities transaction; ask, in writing, which registered entity, if any, will receive the success fee and advise on that leg.

Who did we leave off, and why?

Every firm below is real; what is missing is a behavioral credit I could see. Bailey Southwell serves a "Launching Soon" placeholder with a 2024 copyright, no team page and no transactions; whether it is rebranding or winding down I cannot say, and a holding page is not a track record. Cross Keys Capital is a real bank with a real physician-practice-management franchise, "more than 200 companies" advised, but its deals page is JavaScript-only and returned nothing to any fetch, so no behavioral transaction could be verified; our healthcare hub correctly places it in PPM. Physician Growth Partners (site unreadable to a fetch), Coker Capital (no behavioral evidence, no regulator record) and Edgemont Partners (bot-blocked) established no behavioral credit; Edgemont stays on the hub's post-acute bench. Ziegler (CRD 61, active) and Cain Brothers (a KeyBanc company whose standalone CRD 13649 is now inactive, the business having moved inside KeyBanc) are the registered end of the market, and neither had a behavioral tombstone I could open, the Evidence Inversion in one line. Harris Williams, Houlihan Lokey, Jefferies, Raymond James, Lincoln International, William Blair and Piper Sandler carry zero behavioral adviser-of-record credits I could verify. Two head-to-heads readers ask about: Cain Brothers vs Capstone Partners for a $50M platform, where Cain is the KeyBanc-owned bank with the broader healthcare-services franchise and Capstone is a counter with three undated behavioral tombstones, and neither showed me a behavioral close I could date, so ask both for three; and Cross Keys vs Provident for behavioral, where Provident wins because its ABA credits are on its site and its broker-dealer is in its footer.

Two firms sit in labelled columns rather than on the bench. VMG Health is a valuation and advisory firm, not a sell-side bank: its behavioral page claims "150+ behavioral health engagements over the past 5 years" and its "2024 Review of Behavioral Health M&A Transactions & Trends" is dated November 14, 2024; its use to a seller is the fair-market-value opinion a friendly-professional-corporation or MSO structure needs anyway. Capstone Partners is a data source first: its July 8, 2026 update is the third counter above, and it publishes three undated behavioral tombstones (Drug Research & Development to Behavioral Health Group; Park Bench Group's acquisition of Elements Behavioral Health), while its Pediatric Behavioral Health update is a January 2024 edition whose 2023 figures are not current.

What are behavioral health companies selling for in 2026, and why do platforms and add-ons get different numbers?

At platform scale, a filed 15.0x median next-twelve-month adjusted EBITDA on precedent transactions and 10.1x on public comparables, both from Wells Fargo Securities' analysis in Talkspace's April 2026 proxy; below that scale nobody publishes a verified 2026 private-company multiple, so every range you are quoted is an adviser's opinion or a stale edition. Wells Fargo's public comparables (Hinge Health, LifeStance Health, Progyny, Teladoc Health, Omada Health; market data as of March 5, 2026) carried a 10.1x median and 12.0x mean EV / 2026E adjusted EBITDA, a tech-enabled set that will mislead a residential SUD seller who reads it as a peer group. The precedent set: ten behavioral and benefit-management deals announced January 1, 2020 through March 5, 2026, of which four are pure behavioral platforms, Onex Partners' Newport Healthcare (June 2021), Kelso's Refresh Mental Health (December 2020), TPG's LifeStance Health (April 2020) and Centene's Magellan Health (January 2021).

Capstone Partners' July 8, 2026 update prices the same deal at $835 million, 3.0x EV/revenue and 26.1x EV/EBITDA; both are right, because Capstone's is a trailing-style multiple on a barely profitable target and Wells Fargo's is forward.

The only published sub-sector ladder with an add-on line is the one our healthcare hub carries from FOCUS Investment Banking's December 2025 edition: mental-health platforms 10-14x EBITDA with add-ons at 4-8x, autism/ABA platforms 12-15x, IDD 9-12x, addiction 8-11x. Not re-verified this pass, nine months old, and pre-dating the 2026 SUD fall-off: a shape, not a quote.

The platform-versus-add-on gap is set by five things: scale, management depth below the owner, multi-site and multi-state infrastructure, portable payer contracts, and whether the sponsor already owns a platform in your lane. The 2026 autism example runs the other way from a roll-up: Cathay Capital launched Ascendia Autism Care around a single founding affiliate with 20 centers in eight states and more than 400 clinicians, which Taggart reads as "a firm entering around a single high-quality founding group rather than buying a built rollup," a platform multiple paid to one founder. Underneath every range is the Payer-Mix Ladder, behavioral edition, the sector-native version of the Reimbursement-Mix Multiple Ladder in our healthcare hub: behavioral health is four payer markets, not one, and the multiples diverge because the payer mixes do. Autism/ABA runs on commercial insurance over a state Medicaid EPSDT backbone; IDD is almost entirely Medicaid waiver; residential SUD mixes commercial out-of-network, Medicaid and cash pay; outpatient mental health is commercial-heavy. Taggart's Q2 2026 summary is the underwriting rule in one sentence: buyers are "paying up for clean, in-network, growing businesses and being more diligent on everything else. For an owner, that spread is the whole story."

What does the 2026 reimbursement and regulatory calendar mean for a behavioral health seller?

Six dated rules, and the one every seller fears is the one that carves behavioral health out.

Call the second row the Carve-Out Nobody Reads, a Peony-original frame: the new Medicaid cost-sharing regime does not touch mental health, SUD or CCBHC services, and the work requirement exempts the people most behavioral providers treat. The Braff Group says the same in its 2025 year-end update: behavioral patients are "generally excluded," but "the administrative burdens required to obtain these exclusions may result in otherwise appropriate individuals losing Medicaid coverage," and "the actual impacts will likely not become clear until at least mid-2027." The DEA row is the December 31 cliff: any telebehavioral or MOUD platform signing this autumn is underwriting a flexibility that, as filed, ends inside its own closing window. Medicare's own telehealth waivers are a separate statute, not verified here. Confirm every row with healthcare counsel before you sign an LOI.

Who is buying behavioral health companies in 2026: sponsors, strategics or nonprofits?

Strategics and nonprofits in aggregate, sponsors coming back in autism, and lenders deciding what closes. Capstone Partners, July 8, 2026: "Strategics have dominated dealmaking to date, accounting for 68.2% of total sector volume." Mertz Taggart, Q2 2026: two new sponsor platforms formed, sponsor-backed strategics kept buying in smaller bites, and nonprofit and health-system combinations were "roughly a third of closed traditional volume." The Braff Group, April 2026, on autism: platform activity over the past two years has been "the highest we've seen since 2020." The first-time third is the nonprofit buyer; Merakey and I Am Boundless at up to $1 billion of combined revenue and Brightli and Centerstone at over $1 billion are the proof, and Boundless's CEO cited Medicaid shortfalls outright. For a $3M-EBITDA in-network mental health group, run the hub's Buyer-Universe Depth Test against all three columns. Acadia Healthcare, the largest public pure-play, remains independent as of September 15, 2026, with activist Khrom Capital at 8.81% (Schedule 13D/A, January 23, 2026) and a CEO departure effective January 20, 2026; nothing on its EDGAR file says it is for sale.

The distress file is real and it is concentrated in SUD. BayMark Health Services, the Webster Equity Partners-backed opioid-treatment platform that is the named buyer on three Braff tombstones and one Brentwood tombstone, was the subject of Behavioral Health Business headlines on July 23, 2026 ("creditor takeover") and July 31, 2026 (a Chapter 11 filing "possible in Q3"); I have not confirmed a filing and do not assert one. Mertz Taggart's Q4 2025 report records that Ellie Mental Health's auditors expressed "substantial doubt" about its ability to continue as a going concern in its franchise disclosure documents, and that Omni Health Services, 18 clinics in Pennsylvania and New Jersey, filed for Chapter 11 on November 25, 2025. The lender sentence, verbatim from the same report: "Deals in 2025 took longer to close as lenders tapped the brakes to conduct forensic-level diligence on insurance receivables... Lenders are now slowing down processes to ensure... that target companies have robust 'denials management' processes and verifiable collectability... forcing sellers to open their books for longer, more intrusive audits." In 2025 it was credit committees, not buyers, who slowed behavioral deals, and they slowed them over receivables. That is a data-room argument before it is a banking argument.

What do buyers diligence in a behavioral health sale, and how does 42 CFR Part 2 shape the data room?

Payer mix first, then a file that changes by lane, and then a room built for the fact that your best buyers are your competitors and your clinicians are the business. The items with a primary source behind them: Part 2 compliance evidence after the February 16, 2026 compliance date, consent forms, patient notice and breach-notification alignment, with § 2.25 noted as tolled (89 FR 12472); DEA telemedicine dependence, how much revenue rides on flexibilities that as filed expire December 31, 2026 (90 FR 61301), and MOUD/OTP practices against the rule effective July 9, 2026 (91 FR 34754); Medicaid readiness, which states you operate in, whether any adopted the community-engagement requirement early, and whether you can document the SUD, disabling-mental-disorder and IDD exemptions for your own census (Public Law 119-21, § 71119); receivables and denials management, aged AR by payer, denial and appeal rates and collectability substantiation; and in-network versus out-of-network mix and length of stay, the two SUD screens Taggart named in Q2 2026. Practitioner items with no published source, ours rather than a statistic: licence and accreditation transfer on change of ownership, Certificate-of-Need exposure for psychiatric beds and residential SUD, BCBA supervision-ratio documentation for ABA, waiver-slot concentration for IDD, and single-case-agreement dependence for out-of-network SUD. Two more belong on that list: billing and coding exposure under the False Claims Act, the claim-sample audit a buyer's counsel runs on every behavioral target; and structure, because in corporate-practice-of-medicine states a sponsor cannot own a psychiatry or eating-disorder practice outright, so the deal is an MSO buying the non-clinical assets and a management fee, with a friendly professional corporation holding the licence, and the fair-market-value opinion VMG sells is what makes that fee defensible. The state map is the Regulatory-Overhang Discount in our healthcare hub; your adviser's job is to have priced the structure before the LOI. The quality of earnings and our sell-side due diligence guide sit on top.

Part 2 then decides what does not go in the room. Patient-identifying SUD records are not diligence documents; what a buyer sees is de-identified and aggregate, census, length of stay, payer mix, denial and collection data by plan, and the compliance file itself, with any record-level review handled under a qualified service organization agreement or patient consent, off the general room. The fix for the rest is staged access, run out of a room you control:

• A separate data room per bidder, with visitor groups walling a regional rival off from the sponsor platforms inside one process, so no party sees another's tranche, activity or Q&A.
• Staged disclosure: the teaser and payer-mix summary first; the receivables and denials schedule, the normalisation schedule and the licence and accreditation file in the middle; clinician rosters, contracted rates by plan and referral-source detail last, after a bid you believe.
• NDA gates before the room opens: acknowledge-only Simple NDA on Business and up, Advanced NDA with a countersigned PDF on Data Room and up; one-click revoke on Business and up; link expiry on every tier.
• Per-viewer watermarks on every rendered page, so a forwarded rate schedule traces to one reader. Data Room plan and up.
• Page-level analytics showing which platform spent forty minutes on the out-of-network receivables schedule, the one preparing a retrade.
• Advanced Redaction on the Deal Team plan for schedules that still carry an identifier, plus auto-indexing, structured Q&A and the security layer.

Peony is not an M&A advisor and does not place deals; the firms above do that. We are the confidential room the process runs in: pick your advisor first, then stand up the room. Peony serves 6,800+ customers on exactly this layer, rated 4.8 on G2 and 4.9 on Capterra, and signs a Business Associate Agreement on request; the room is a document-handling control, not a Part 2 compliance opinion, which comes from counsel. The Data Room plan is $52 per admin per month billed annually, the tier a sell-side process wants: dynamic watermarking, Advanced NDA, per-file permissions and unlimited rooms. Business is $30 per admin per month; Deal Team is $64 per admin per month billed annually with a four-admin minimum; a Free tier exists (pricing). The build is in our M&A data room playbook and how to write a CIM; the recurring credentialing, payer-audit and funder room a behavioral practice runs all year, a different job from a sale, is in our behavioral health data room guide.

What do behavioral health M&A advisers charge?

A retainer plus a success fee, and not one firm on this bench publishes a fee percentage, searched September 15, 2026. The only filed fee shape in behavioral health is Wells Fargo's on Talkspace: a portion "became due and owing as of March 6, 2026, the date Wells Fargo rendered its fairness opinion," the remainder "contingent upon the closing," and an aggregate that "constitutes less than 1% of Wells Fargo's consolidated annual revenue," a fraction of the bank's revenue that says nothing about a rate. Below that scale the conventions in our M&A advisor fees guide apply: the double-Lehman scale or a negotiated flat percentage with a stated minimum, a monthly retainer credited against the success fee, and every term in writing. Settle two behavioral-specific terms first: whether the fee base is cash at close net of rollover, and what your banker has been paid by the buyer or its sponsor in the last two years.

So which behavioral health M&A adviser should you hire?

The one whose evidence sits in your lane, because behavioral health is three markets and the buyer sets do not overlap. An SUD operator prices on census, length of stay and in-network mix in a lane running down 28% with two closings last quarter: Brentwood Capital Advisors for a dated SUD record, The Braff Group for the buyer map. An outpatient mental health or psychiatry group prices on provider productivity and contracted rates in the lane that took all six growth rounds in Q2 2026: Provident for the PCF Capital Markets registration chain and a psychiatric-hospital credit, Brentwood for the two Galen Mental Health platform sales, with its Comvest credit noted as buy-side, Mertz Taggart when the fight is over timing. An ABA or IDD provider prices on payer concentration, BCBA ratios and waiver slots in the only lane up on the year: Braff for the Stepping Stones and LEARN map, Provident for two named ABA sales, VERTESS for IDD, waiver-funded and nonprofit sellers.

Related resources

• Best healthcare M&A advisors, the hub this spoke deepens, and the best dental M&A advisors sibling spoke.
• Behavioral health data room, the recurring credentialing, audit and funder room, and best HIPAA-compliant data rooms.
• Best M&A advisors, M&A advisor fees and M&A advisor vs broker vs investment bank.
• M&A data room, how to write a CIM, quality of earnings and sell-side due diligence.
• Pricing and the M&A, due diligence and private equity solution pages.

Frequently asked questions

Medicaid rate cuts are coming — is 2026 a bad time to sell a behavioral health company?

It depends which behavioral market you are in, because 2026 runs two ways: The Braff Group's Mid-Year 2026 Update has autism services up 58% on 2025 and substance use disorder down 28%, aggregate up 3.4%, while Mertz Taggart's Q2 2026 report counts 27 closed transactions, 21 of them traditional M&A, the lightest quarter for closed traditional volume in its data set going back to 2022, and two addiction closings, the lowest quarterly total in its data set. The statute behind "Medicaid cuts" says something else: Public Law 119-21's work requirement starts no later than January 1, 2027 and exempts people with a substance use disorder, a disabling mental disorder or an IDD, and its cost-sharing regime, from October 1, 2028, expressly excludes mental health and SUD services. For an in-network, growing mental health or ABA group, Kevin Taggart's read is that buyers are paying up with little competing supply; for an out-of-network residential SUD program, waiting does not fix the payer mix a buyer will price.

How does mental health parity rule uncertainty affect what my company is worth?

Parity has moved from a federal compliance calendar to a diligence and reps-and-warranties question, and that is how a buyer prices it. The 2024 parity final rule (89 FR 77586, effective November 22, 2024) added comparative-analysis requirements for non-quantitative treatment limitations; on May 15, 2025 the Departments of Labor, HHS and Treasury said they would not enforce what is new relative to the 2013 rule, and an EBSA field assistance bulletin in early September 2026 narrowed enforcement to separate treatment limitations, medical-necessity standards and network adequacy. The statutory MHPAEA obligation is untouched. If your revenue leans on out-of-network rates or single-case agreements, parity is the legal theory behind those rates and a buyer will test its durability plan by plan; if you are in-network, the exposure is mostly the payer's. Confirm the current posture with healthcare counsel before an LOI.

Who are the best M&A advisers for behavioral health companies in 2026?

Seven firms carry checkable behavioral adviser-of-record evidence, and they split by evidence type. Brentwood Capital Advisors (Nashville, CRD 118712) is the only firm publishing a dated, role-labelled behavioral tombstone series, ten credits from 2020 to 2025. The Braff Group (Pittsburgh) publishes 380 transaction pages, each stating "BRAFF WAS SELLSIDE ADVISOR" and naming the lead banker, with no dates. VERTESS (Dallas-Fort Worth) publishes 112 role-labelled deals across mental health, SUD, IDD and autism-adjacent services, with one dated credit in a primary release. Wells Fargo Securities and J.P. Morgan are named in Talkspace's SEC-filed proxy on the $5.25-per-share sale to Universal Health Services; below roughly $500 million they are the bank across the table, not your hire. Provident Healthcare Partners (Boston) has three named ABA and mental-health credits and registration through PCF Capital Markets, LLC (CRD 290765). Mertz Taggart publishes the sector's only unbroken quarterly deal count and no adviser-of-record evidence. None of the three behavioral-native boutiques appears in the SEC adviser-info database.

Do I need a behavioral health specialist, or will a business broker or generalist bank do for a $15M company?

A specialist, once your business is large enough that several sponsor platforms in your lane would bid, and because no boutique on this bench publishes a deal-size range, the test is not the label a firm gives itself but registration and closed transactions in your lane. The shape of the market: a regional business broker with two or three behavioral closings can serve a single-site practice whose buyer is a local operator; Brentwood Capital Advisors, The Braff Group, VERTESS and Provident Healthcare Partners are lower-middle-market sell-side firms whose published behavioral credits are owner-operator sales; above roughly $500 million you are in Wells Fargo Securities and J.P. Morgan territory, the only two with a filed behavioral credit, and it was an $835 million public-company deal. A generalist bank without a behavioral close cannot build the buyer list, because the buyers are lane-specific: BayMark and Odyssey in SUD, The Stepping Stones Group and LEARN in ABA, Caregiver, Inc. and VersiCare in IDD, Galen Mental Health and Refresh Mental Health in outpatient mental health. For a $15M-revenue outpatient group, all four boutiques clear the size; ask each which of its last five behavioral closes was under $20M of revenue and who bought it.

Mertz Taggart vs The Braff Group — which is better for selling my behavioral health company?

Braff on relationship evidence, Mertz Taggart on market data, and neither publishes a deal date or a broker-dealer registration, so three facts decide it. Buyer map: Braff's behavioral tombstones name BayMark Health Services three times, The Stepping Stones Group three times, LEARN Behavioral or LEARN It four times, Webster Equity Partners twice and Refresh Mental Health twice, each page naming the managing director who led it; Mertz Taggart publishes no transaction count and no named buyer I could verify. Data: Mertz Taggart's Behavioral Health M&A Report has run every quarter since 2020 with separate mental health, addiction and autism/IDD pages, which is why the trade press quotes it. Lane: Braff is the deeper call for an SUD, ABA or IDD seller whose likely buyer is on that map; Mertz Taggart when you want the firm that counts the market advising on timing.

Who are the top investment banks for substance use treatment centres, and who actually closes ABA and eating-disorder deals?

For a substance use disorder operator, the firms with published SUD adviser-of-record evidence are Brentwood Capital Advisors (Georgia Recovery Campus to First Steps Recovery and Avesi Partners, 2025; Discovery Point Retreat to Eagle Capital Health Ventures, 2024; Mt. Sinai to BayMark Health Services, 2021, years as the firm states them) and The Braff Group (three sales to BayMark, Walden to Pyramid Healthcare, Lifeskills South Florida to Odyssey Behavioral Healthcare, undated). For ABA: Braff (three sales to The Stepping Stones Group, four to LEARN Behavioral or LEARN It), Provident Healthcare Partners (New England ABA to The Stepping Stones Group; Comprehensive Autism Center to The Speech Pathology Group) and Brentwood (Family Support Center to Speech Pathology Group, 2020; Westside Children's Therapy to Achieve Partners, 2025). For eating disorders, no counter publishes a separate deal count and I could verify no 2025 or 2026 platform transaction; the only firm-published credits are Braff's Atlanta Center for Eating Disorders to Walden Behavioral Care and Walden to Pyramid, undated.

Platform valuation vs add-on valuation — how big is the multiple difference in behavioral health?

Large enough that it is the first question to settle, and the only filed numbers put the platform end at 15.0x: Wells Fargo Securities' precedent set in Talkspace's April 2026 proxy, ten behavioral and benefit-management deals announced January 2020 to March 2026 including Onex's Newport Healthcare, Kelso's Refresh Mental Health and TPG's LifeStance, carries a 15.0x median next-twelve-month adjusted EBITDA, and its public comparables sat at a 10.1x median 2026E adjusted EBITDA as of March 5, 2026. The only published ladder with an add-on line is FOCUS Investment Banking's December 2025 edition, carried in our healthcare hub and not re-verified: mental-health platforms 10-14x, add-ons 4-8x. What moves you from add-on to platform is scale, management depth below the owner, multi-site and multi-state infrastructure, portable payer contracts and whether the sponsor already owns a platform in your lane.

What EBITDA multiple will my outpatient mental health group or ABA company sell for in 2026, and how do the two compare?

Nobody publishes a verified 2026 sub-sector multiple for private behavioral companies, so any number you are quoted is an adviser's opinion or a stale edition. The ladder our healthcare hub carries from FOCUS Investment Banking's December 2025 edition, not re-verified and pre-dating the 2026 SUD fall-off, puts autism/ABA platforms at 12-15x EBITDA, mental-health platforms at 10-14x with add-ons at 4-8x, IDD at 9-12x and addiction at 8-11x. The filed reference points are Wells Fargo's 15.0x median NTM adjusted EBITDA on precedents and 10.1x on public comparables (Talkspace proxy, market data as of March 5, 2026); Capstone Partners prices the Talkspace deal itself at 26.1x EV/EBITDA in its July 8, 2026 update, a trailing multiple on a barely profitable target. ABA is priced per clinic location as well as on EBITDA because a center is a capacity unit with a BCBA supervision ratio attached; an outpatient mental health group is priced on provider productivity, contracted rates, telehealth share and how much clinical work the owner still does.

Buyers keep discounting my revenue because it is Medicaid-heavy — what can I do about it?

Stop arguing about Medicaid as a category and make the buyer model it the way it is paid: by state, program, managed-care plan and rate history. Behavioral health is four payer markets: autism/ABA runs on commercial insurance over a state Medicaid EPSDT backbone, IDD is almost entirely Medicaid waiver, residential SUD mixes commercial out-of-network, Medicaid and cash pay, and outpatient mental health is commercial-heavy, so an IDD provider should never be argued out of Medicaid because there is nothing else to be in. The evidence that narrows the discount is multi-year rate history by plan, contract renewal dates, denial and appeal rates, authorization throughput and aged receivables by payer, because in 2025 it was lenders doing forensic-level diligence on insurance receivables who slowed behavioral closings (Mertz Taggart, Q4 2025). The statute helps: mental health and SUD services are expressly excluded from Public Law 119-21's Medicaid cost-sharing regime, and SUD, disabling-mental-disorder and IDD individuals are exempt from its work requirement. What only diversification fixes is single-plan concentration.

Will my out-of-network and single-case-agreement revenue count in EBITDA?

It counts, but not at the same multiple as in-network revenue, and it is the line item that produces the retrade. A quality-of-earnings analysis separates contracted in-network revenue from out-of-network claims and single-case agreements, then tests each for collectability: billed, allowed, paid, days to cash and denial rate. Out-of-network revenue that rests on a payer's current policy and a parity theory the 2024 rule no longer federally enforces gets haircut or excluded; single-case agreements are defended one at a time, on written terms, renewal history and the share of census they cover. Kevin Taggart's Q2 2026 read is explicit: platforms are selective on payer mix and length of stay, and SUD is where the gap between good assets and everything else is widest. Put the payer-level receivables schedule and the denials-management process in the room before the LOI.

How long does it take to sell an addiction treatment centre, and what licensure and Medicaid change-of-ownership approvals sit on the critical path?

No bank or trade body publishes a behavioral-specific timeline, so the honest benchmark is the generic healthcare range in our healthcare M&A advisors hub, six to nine months from kickoff to close and longer when regulatory review is on the critical path, which in SUD it usually is. Financial diligence rarely sets the calendar; the approvals do. The practitioner sequence, our framing rather than a published statistic: state facility licence transfer or new-licence application on change of ownership, Medicaid and managed-care change-of-ownership notices and re-enrolment, DEA and state controlled-substance registrations for any MOUD or OTP line, and Joint Commission or CARF accreditation transfer, each on its own clock, with payer re-credentialing running in parallel. Three dated items belong on the calendar: the 42 CFR Part 2 compliance date of February 16, 2026 has passed; DEA's telemedicine flexibility for controlled substances runs January 1 through December 31, 2026 as filed; and the SUPPORT Act medication-assisted treatment rule took effect July 9, 2026.

How do I handle 42 CFR Part 2 records in the data room when the bidders include competitors who would hire my clinicians?

You do not upload patient-identifying substance use disorder records for diligence at all; Part 2 restricts their disclosure, and the compliance date for the 2024 final rule (89 FR 12472) passed on February 16, 2026, so a buyer's counsel will ask for your post-date consent forms and patient notice, not your charts. What goes in the room is de-identified and aggregate: census, length of stay, payer mix, denial and collection data by plan, and the compliance file itself, with any record-level review handled under a qualified service organization agreement or patient consent, off the general room. For a $20M-revenue residential SUD operator running four sponsor-backed platforms and one regional rival, I would run a separate Peony data room per bidder so no party sees another's tranche, activity or Q&A; stage disclosure so clinician rosters, contracted rates by plan and referral-source detail sit behind a later gate until a bid is real; put an NDA gate in front of anything that opens, Simple NDA on the Business plan and Advanced NDA with a countersigned PDF on Data Room; use per-viewer dynamic watermarks on the Data Room plan so a leaked rate schedule traces to the person who opened it; and read page-level analytics to see which bidder actually spent time on the payer-mix schedule. The Data Room plan is $52 per admin per month billed annually with unlimited free viewers, Business is $30, and a Free tier exists; Peony signs a Business Associate Agreement on request and serves 6,800+ teams on exactly this layer. The room is a document-handling control, not a Part 2 compliance opinion.

How do buyers normalise EBITDA for my owner-clinician compensation?

They replace what you pay yourself with what it would cost to hire someone else to do each of your jobs, and they rarely accept your version of that number. If you are the clinical director, a treating clinician and the CEO, the buyer builds a replacement-cost adjustment for each role at market salary plus benefits, and the sum often exceeds the owner draw you were adding back, which lowers adjusted EBITDA rather than raising it. The add-backs that get challenged are related-party rent on a facility you own, family payroll, and start-up losses on a new site you want excluded and the buyer wants annualised. A sell-side quality of earnings is worth its cost here because the disputed adjustments are large relative to EBITDA. Underneath is the key-person question: if you are the only licensed clinical director, the buyer is pricing the risk that the licence, the referral relationships and the culture leave with you, and the answer is a documented deputy, a transition and non-solicitation arrangement, and a rollover stake that keeps you aligned.

What do behavioral health M&A advisers charge, and how much rollover equity will a platform require?

Not one firm on this bench publishes a fee percentage, so the only filed fee shape in behavioral health is Wells Fargo's on Talkspace: part payable when it delivered its fairness opinion on March 6, 2026 and the remainder contingent on closing, with the aggregate disclosed as less than 1% of Wells Fargo's consolidated annual revenue, which tells you nothing about a rate. Below that scale the conventions in our M&A advisor fees guide apply: a monthly retainer credited against a success fee, and the terms worth fighting over are the minimum fee, the tail period, exclusivity and whether the fee base is enterprise value or cash at close. On rollover, no behavioral-specific benchmark is published; a sponsor platform will ask a founder to roll a meaningful share of proceeds into its holding company, the paper value of that stake is set by the platform's entry multiple and debt, and the governance terms decide whether it is a second bite or a trap: tag-along and drag-along rights, put rights on departure and what happens in a lender-driven recapitalisation. Rolled equity is a security, so ask which registered entity advises on that leg.

A PE-backed platform sent me an unsolicited letter of intent — should I run a process anyway?

Usually yes, because an unsolicited LOI is priced to the platform's accretion target, not to what a second bidder would pay, and the filed record shows what competition is worth: UHS's first offer for Talkspace in December 2025 was $4.05 to $4.25 per share, its February 2026 offer $5.00, the Board countered at $5.50 through Wells Fargo and the deal signed at $5.25, an increase the proxy describes as approximately 30%. The tells of a fixed-accretion offer are a price stated before anyone has seen your payer mix, a thin diligence list and a short exclusivity ask. The question underneath is what happens to your clinical model afterward, and the 2026 tape answers it two ways: sponsor-backed strategics still buying in smaller bites and nonprofits taking roughly a third of closed volume (Mertz Taggart, Q2 2026), while Ellie Mental Health's going-concern language and the creditor headlines around BayMark show what a stretched platform looks like from inside. Negotiating directly is right when your buyer is one health system you know and the price already clears a defensible valuation.

Sources

• Mertz Taggart, Q2 2026 Behavioral Health M&A Report (August 2026) and Q4 2025 report (February 19, 2026). https://mertztaggart.com/post/q2-2026-behavioral-health-m-a-report; https://mertztaggart.com/post/q4-2025-behavioral-health-m-a-report
• The Braff Group, Mid-Year 2026 Update (August 2026) and 2025 Behavioral Health Year End M&A Update (April 2026). https://thebraffgroup.com/resource/mid-year-2026-update-the-rebound-continues/; https://thebraffgroup.com/resource/health-care-services-2025-update-2-2-2/
• Capstone Partners, Behavioral Healthcare Services M&A Update (July 8, 2026); Pediatric Behavioral Health Services M&A Update (January 2024 edition). https://www.capstonepartners.com/insights/report-behavioral-health-services-ma-update/
• Talkspace, Inc., DEFM14A filed April 20, 2026; 8-K, Form 25 and Form 15 filings of August 17 and 27, 2026. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001803901
• Acadia Healthcare Company, Inc., Schedule 13D (October 1, 2025), 13D/A (January 23, 2026) and 8-K (January 23, 2026). https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001520697
• Public Law 119-21, §§ 71119 and 71120, enrolled text. https://www.govinfo.gov/app/details/PLAW-119publ21
• 89 FR 12472 (42 CFR Part 2 final rule); 90 FR 61301 (DEA fourth temporary telemedicine extension); 91 FR 34754 (SUPPORT Act MAT rule); 89 FR 77586 (MHPAEA final rule). https://www.federalregister.gov/citation/89-FR-12472; https://www.federalregister.gov/citation/90-FR-61301; https://www.federalregister.gov/citation/91-FR-34754; https://www.federalregister.gov/citation/89-FR-77586
• MHPAEA non-enforcement statement of May 15, 2025 (AHA, Ogletree, Proskauer, APA reporting); EBSA field assistance bulletin of early September 2026 (National Law Review, Mayer Brown, September 11-13, 2026).
• Firm sites read September 15, 2026: brentwoodcap.com, thebraffgroup.com, vertess.com (including the PRNewswire release of November 15, 2024), providenthp.com, vmghealth.com, mertztaggart.com; SEC adviser-info firm database for CRD numbers; 15 U.S.C. § 78o(b)(13). https://www.law.cornell.edu/uscode/text/15/78o
• Behavioral Health Business headlines of June 27, 2025, May 12, 2026, July 23, 2026 and July 31, 2026.

About the author: Sean Yu is the co-founder of Peony, the data room platform used by 6,800+ customers across M&A, fundraising, and diligence workflows, including behavioral health operators and their advisers running confidential sales. Before Peony, Sean worked in M&A at Nomura, early-stage VC at Backed VC and growth equity at Target Global. Peony is not an M&A advisor; it is the confidential room a deal process runs in. Contact: sean@peony.ink • LinkedIn.